Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Medtronic
Dow
Harvard Business School
Colorcon
McKinsey

Last Updated: September 26, 2022

JELMYTO Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which patents cover Jelmyto, and what generic alternatives are available?

Jelmyto is a drug marketed by Urogen Pharma and is included in one NDA. There are two patents protecting this drug.

This drug has nine patent family members in six countries.

The generic ingredient in JELMYTO is mitomycin. There are seven drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the mitomycin profile page.

Summary for JELMYTO
International Patents:9
US Patents:2
Applicants:1
NDAs:1
Clinical Trials: 5
Formulation / Manufacturing:see details
What excipients (inactive ingredients) are in JELMYTO?JELMYTO excipients list
DailyMed Link:JELMYTO at DailyMed
Drug patent expirations by year for JELMYTO
Recent Clinical Trials for JELMYTO

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Mayo ClinicPhase 2
National Cancer Institute (NCI)Phase 2
National Cancer Institute (NCI)Phase 3

See all JELMYTO clinical trials

US Patents and Regulatory Information for JELMYTO

JELMYTO is protected by two US patents and two FDA Regulatory Exclusivities.

Patents protecting JELMYTO

Material and method for treating internal cavities
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Material and method for treating internal cavities
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

FDA Regulatory Exclusivity protecting JELMYTO

INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH LOW-GRADE UPPER TRACT UROTHELIAL CANCER (LG-UTUC)
Exclusivity Expiration: See Plans and Pricing

NEW PRODUCT
Exclusivity Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Urogen Pharma JELMYTO mitomycin POWDER;PYELOCALYCEAL 211728-001 Apr 15, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Urogen Pharma JELMYTO mitomycin POWDER;PYELOCALYCEAL 211728-001 Apr 15, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Urogen Pharma JELMYTO mitomycin POWDER;PYELOCALYCEAL 211728-001 Apr 15, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Urogen Pharma JELMYTO mitomycin POWDER;PYELOCALYCEAL 211728-001 Apr 15, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for JELMYTO

See the table below for patents covering JELMYTO around the world.

Country Patent Number Title Estimated Expiration
World Intellectual Property Organization (WIPO) 2011089604 See Plans and Pricing
Israel 230530 חומרים ושיטה לטיפול בחללים של הגוף (Materials and method for treating internal body cavities) See Plans and Pricing
European Patent Office 2734187 MATÉRIAUX ET MÉTHODE DE TRAITEMENT DE CAVITÉS CORPORELLES INTERNES (MATERIALS AND METHOD FOR TREATING INTERNAL BODY CAVITIES) See Plans and Pricing
Germany 212011100034 See Plans and Pricing
World Intellectual Property Organization (WIPO) 2013011504 See Plans and Pricing
European Patent Office 2525777 MATÉRIEL ET PROCÉDÉ DE TRAITEMENT DE CAVITÉS INTERNES (MATERIAL AND METHOD FOR TREATING INTERNAL CAVITIES) See Plans and Pricing
Spain 2732150 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
Medtronic
Harvard Business School
AstraZeneca
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.